Medical Data Vision Co.,Ltd.
3902・Prime Market・Information & Communication
Medical Data Vision Co.,Ltd. (Single Segment)
Medical data network business that integrates the collection, accumulation, and utilization of medical data end-to-end
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales | ¥6,539 million | ¥5,907 million | ↑ |
| Operating income | ¥349 million | ¥4 million | ↑ |
| Ordinary income | ¥361 million | -¥510 million | ↑ |
| Ordinary income margin (ratio of ordinary income to net sales) | 5.5% | -8.6% | ↑ |
| ROE (Return on Equity) | 9.1% | -21.6% | ↑ |
Business Details
The Group operates in a single segment, the medical data network business. Through its management support systems for medical institutions, it collects and accumulates DPC data and other information, building Japan's largest clinical database, "Sakura DB," covering over 55 million patients. This database is leveraged for data utilization services aimed at pharmaceutical companies and research institutions, while also offering services to patients and consumers through the PHR system "Karteko" and the health checkup system "Alpha Salus." Services are organized into three categories: data network services, data utilization services, and other services.
Recent Overview
In the fiscal year ended December 2025, net sales increased 10.7% and operating income improved significantly, resulting in a return to profitability in the final year of the medium-term management plan
The consolidated fiscal year under review (fiscal year ended December 2025) marked the final year of the medium-term management plan. Net sales increased across all service categories to ¥6,539 million (up 10.7% year on year). Data utilization services achieved a record high of ¥4,622 million (up 10.9% year on year), driven by the strengthening of the sales workforce. Selling, general and administrative expenses decreased to ¥4,204 million (down 2.9% year on year) due to reductions in advertising and R&D expenses, resulting in a significant improvement in operating income to ¥349 million (versus ¥3 million in the prior year). Profit attributable to owners of parent turned positive at ¥280 million (compared with a net loss of ¥791 million in the prior year).
Key Products
Growth Drivers
- Organic sales growth in data utilization services driven by the expansion and strengthening of the sales workforce (achieved a record high of ¥4,622 million)
- Expansion of MDV Act's target audience beyond DPC hospitals, increasing the customer base and strengthening the data acquisition infrastructure
- Start of revenue recognition from the fourth quarter following the restructuring of the Alpha Salus installation and setup framework
- Differentiated data assets centered on "Sakura DB," Japan's largest clinical database covering over 55 million patients
- Reduction in selling, general and administrative expenses (down 2.9% year on year) through cuts in advertising and R&D expenses
Risks
- The installation and setup of Alpha Salus at health checkup facilities took longer than expected, resulting in a significant delay relative to the sales plan for the fiscal year under review
- Upward cost pressure due to increased outsourcing expenses for analytical work in data utilization services
- Risk of investment losses related to the equity-method affiliate, Sensing Inc.
- Risk of extraordinary losses, including a valuation loss on investment securities recorded in the fiscal year under review (¥290,553 thousand)
- High costs of maintaining advanced security and regulatory compliance burdens related to the collection and management of medical data
Last updated: March 24, 2026